Abstract:

Purpose: In the treatment of chronic hepatitis C in our country since June 2016, we aimed to investigate the effectiveness of these treatments by providing real life data of the treatment responses of direct-effective antiviral agents that have been used in our country since June 2016. Materials and Methods: Patients who were treated with direct-effective antiviral agents due to chronic hepatitis C between July 2017 and September 2018 in our hospital were retrospective treatment responses examined. Clinical, demographic characteristics of patients, side effects during treatment, 4, 12 and 24. Weekly HCV RNA levels were recorded from the hospital database. Results: The research population (Ombitasvir+Paritaprevir+Ritonavir)+Dasabuvir was composed of a total of 19 chronic hepatitis C patients, including 7 patients (36.8%) and 12 patients (63.2%) using (Ombitasvir+Paritaprevir+Ritonavir)+Dasabuvir+Ribavir. The age range of patients was 20-69 years, with an average of 43.8±13.6 years and 57.9% (n:11) men. In 42.1 percent of patients (n:8) genotype 1a, in 36.8 percent (n:7) genotype 1b and in 21.1 percent (n:4) genotype 4 was. In patients using OPrD, the rate of patients with RNA levels 0 in the 4th week was 28.6%, and the rate of patients below <12 IU/ml was 42.9%, and in all patients in the 12th and 24th weeks the rate of RNA was 0 (p<0,001). In patients using OPrD+rib, the rate of patients with RNA levels 0 in the 4th week was 58.3%, and the rate of patients under <12 was 33.3%, 12 and 24. The level of RNA in all patients per week was 0 (p<0,001). The permanent viral response rate of antiviral agents that are directly effective in chronic hepatitis C treatment is 100% in our real life data and are well-tolerable medications.

Keywords: